Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Santhera Secures Exclusive Rights from NIH

Published: Monday, June 10, 2013
Last Updated: Monday, June 10, 2013
Bookmark and Share
Santhera has obtained the exclusive rights to the use patent for idebenone in ppMS granted in the USA.

Santhera Pharmaceuticals has announced that it has obtained an exclusive license from the National Institutes of Health (NIH) to its rights on a patent granted in the USA for the use of idebenone for the treatment of primary progressive Multiple Sclerosis (ppMS), a currently untreatable disease affecting about 40,000 patients in the Unites States.

The NIH is investigating the efficacy of Catena® (idebenone) in ppMS in a placebo-controlled Phase II clinical trial.

Lead by the Neuroimmunology Branch of the National Institute of Neurological Disorders and Stroke (NINDS), the NIH is investigating the efficacy of Catena® (idebenone) in patients with ppMS in a double-blind, placebo-controlled Phase II clinical trial (IPPoMS trial).

Santhera is providing study medication under a clinical trial agreement which gives Santhera the rights to the results. Santhera has now obtained the exclusive rights to the use patent for idebenone in ppMS granted in the USA.

Patients who complete the IPPoMS trial can enter into a 12-months open-label extension trial for which Santhera and the NIH recently signed a Materials Cooperative Research and Development Agreement (M-CRADA).

"Patients with ppMS do not respond to immunomodulatory therapies with proven efficacy in relapsing remitting MS," said Bibiana Bielekova, M.D, the principal investigator of the IPPoMS trial and Chief of the Neuroimmunology Disease Unit at the NINDS.

Bielekova continued, "Accumulating data indicate that mitochondrial dysfunction and related oxidative stress may play a major role in the pathogenesis of progressive MS. Idebenone enhances mitochondrial function and acts as an anti-oxidant against membrane damage in laboratory models and is a rational treatment choice in ppMS based on these pharmacological properties. Recruitment is proceeding well in the IPPoMS trial and we are excited about the opportunity to study the potential of idebenone in this currently untreatable disease."

"We are very enthusiastic about this collaboration and about the progress currently being made. ppMS is a disease with high medical need. In contrast to other forms of MS, there is currently no treatment option available for the 10-15 % of MS patients affected by this primary progressive subtype," commented Nick Coppard, Santhera's Head of Development.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Tuesday, July 21, 2015
CHMP Recommends Granting a Marketing Authorization for Santhera's Raxone®
Raxone® (idebenone) for the treatment of visual impairment in adolescent and adult patients with LHON.
Friday, June 26, 2015
Santhera Update on Pre-NDA Meeting with FDA
Company plans to submit a New Drug Application for Raxone®/Catena® (idebenone) in Duchenne Muscular Dystrophy.
Tuesday, June 16, 2015
Santhera's Positive Phase III Trial in DMD Patients Published in The Lancet
First successful Phase III trial in DMD shows Raxone®/Catena® preserves respiratory function.
Thursday, April 23, 2015
Santhera Receives FDA Fast Track Designation for Raxone®/Catena®
Fast Track designation for the treatment of Duchenne Muscular Dystrophy.
Friday, April 10, 2015
Santhera Repositions Omigapil in Congenital Muscular Dystrophy
Company initiates clinical development program with public-private partners.
Thursday, July 17, 2014
Santhera Announces Successful Outcome of Phase III Study with Catena®/Raxone® in DMD
Positive outcome indicates that Catena®/Raxone® can mitigate respiratory weakness and dysfunction.
Tuesday, May 27, 2014
Santhera Closes License-Back Deal with Takeda
Agreement with Takeda to license back previously granted European rights to Catena® in DMD.
Friday, September 27, 2013
Santhera and Ipsen Renegotiate Fipamezole Licensing Agreement
Santhera regains worldwide rights for fipamezole.
Tuesday, January 24, 2012
Santhera Obtains US Patent for Use of Catena® in the Treatment of Muscular Dystrophies
The patent in the United States is supplemented by a similar patent in the European Union granted in 2010.
Wednesday, August 24, 2011
Data from Santhera's RHODOS Study to Be Presented at the European Neurological Society 2011 Meeting
Results from the RHODOS study evaluate the efficacy of Catena® in Leber Hereditary Optic Neuropathy.
Tuesday, June 07, 2011
Fipamezole Transition from Biovail Completed - Program Well Advanced Towards Phase III
Fipamezole is being developed as a potential first treatment of Dyskinesia in Parkinson's Disease.
Wednesday, February 23, 2011
Santhera Licenses Melanocortin-4 Receptor Antagonist Program to BioLineRx
BioLineRx acquires all rights to develop, sub-license and commercialize the compound.
Friday, October 15, 2010
Santhera Licenses Melanocortin-4 Receptor Antagonist Program to BioLineRx
BioLineRx acquires all rights to develop, sub-license and commercialize the compound.
Thursday, October 14, 2010
Santhera and Ipsen Enter into Licensing Agreement for Fipame-zole for the Treatment of Dyskinesia in Parkinson's Disease
Ipsen acquires the rights to fipamezole outside the United States, Canada and Japan for an upfront payment of EUR 13 million.
Friday, September 03, 2010
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
How To Keep Your Rice Arsenic-Free
Researchers at Queen’s University Belfast have made a breakthrough in discovering how to lower worrying levels of arsenic in rice that is eaten all over the world.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Computer Model Could Explain how Simple Molecules Took First Step Toward Life
Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!